A team of scientists from Germany recently investigated whether hyperactivation of immune receptors that recognize the Fc part of an IgG molecule (FcγR) can lead to immunopathologic changes in ...
Non-clinical evidence supporting the upcoming CLD-201 clinical trial: Cell-based oncolytic virotherapy for multiple solid tumors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
Imagine a forest fire. Flames jump from tree to tree, leaving destruction in their wake. Only the trees burn, but the fire wreaks havoc on the entire ecosystem. Birds have nowhere to build nests; the ...
NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA) to mediate antibody-dependent cellular cytotoxicity (ADCC). Potentiating therapeutic mAb-mediated CD16 activation of NK cells is an ...
Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers. This is an ASCO Meeting Abstract from the 2017 ASCO Annual ...
VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results